Redx Pharma plc Redx to Present at Keystone Symposia
May 03 2023 - 2:00AM
RNS Non-Regulatory
TIDMREDX
Redx Pharma plc
03 May 2023
REDX PHARMA PLC
("Redx" or "the Company")
Redx to Present Additional Preclinical Efficacy of RXC007 and
DDR1/2 Inhibitors in Cancer-Associated-Fibrosis Models at The
Resistant Tumour Microenvironment, Keystone Symposia
Alderley Park, UK, 3 May 2023 Redx (AIM:REDX), the
clinical-stage biotechnology company focused on discovering and
developing novel, small molecule, highly targeted therapeutics for
the treatment of cancer and fibrotic disease announces additional
preclinical data from the company's fibrosis portfolio including
data on lead asset RXC007, and D iscodin Domain Receptor ( DDR) 1/2
inhibitors will be presented both orally and in a poster, at The
Resistant Tumour Microenvironment, Keystone Symposia (7-10 May
2022, Vancouver, BC, Canada).
During the session on Wednesday 10(th) May 0830-1130am PDT: '
Friend or Foe: Should we Target Cancer Associated Fibroblasts and
the ECM?' Redx Senior Scientist, Dr. Daniel Wilcock will discuss if
targeting tumor fibrosis with small molecule inhibitors of Rho
Associated Coiled Coil Containing Protein Kinase 2 (ROCK2) or
DDR1/2 improves therapy response in preclinical models of
pancreatic ductal adenocarcinoma (PDAC) and triple negative breast
cancer (TNBC) . Data presented will be from the Company's lead
fibrosis asset, RXC007 as well as the DDR discovery programme,
which further complements the data set presented last year at the
Extracellular Matrix Pharmacology Congress by collaboration
partner, the Garvan Institute of Medical Research.
In addition to Dr Wilcock's presentation, Redx will present a
poster which details the potential of RXC007 in an aggressive
patient derived xenograft model of PDAC in combination with
standard of care (SoC) chemotherapy, and DDR1/2 inhibition in a
TNBC model in combination with anti-PD-1.
RXC007, the Company's lead asset, is a highly potent, selective
and orally-active ROCK2 inhibitor targeting multiple diseases
associated with fibrosis, initially being developed for
interstitial lung diseases. A Phase 2a study assessing RXC007 as a
potential treatment for patients with idiopathic pulmonary fibrosis
(IPF) is expected to report topline data in Q1 2024.
Details of the presentation are as follows:
Title: Targeting tumor fibrosis with small molecule
inhibitors of ROCK2 or DDR1/2 improves therapy
response in preclinical models of PDAC &TNBC
Session: Friend or Foe: Should we Target Cancer Associated
Fibroblasts and the ECM?
Day/Date: Wednesday 10(th) May, 2023
Time: 08:30-11:30 am PDT
A copy of the poster will be made available on the Company's
website following the presentation at:
https://www.redxpharma.com/scientific-publications/
For further information,
please contact:
Redx Pharma Plc T: +44 (0)1625
UK Headquarters 469 918
Caitlin Pearson, Head of Communications
ir@redxpharma.com
Lisa Anson, Chief Executive
Officer
US Office
Peter Collum, Chief Financial
Officer
SPARK Advisory Partners (Nominated T: +44 (0)203
Adviser) 368 3550
Matt Davis/ Adam Dawes
WG Partners LLP (Joint Broker) T: +44 (0)203
705 9330
Claes Spång/ Satheesh Nadarajah/
David Wilson
Panmure Gordon (UK) Limited T: +44 (0)207
(Joint Broker) 886 2500
Rupert Dearden/ Freddy Crossley/
Emma Earl
FTI Consulting T: +44 (0)203
727 1000
Simon Conway/ Ciara Martin
About Redx Pharma Plc
Redx Pharma (AIM: REDX) is a clinical-stage biotechnology
company focused on the discovery and development of novel, small
molecule, highly targeted therapeutics for the treatment of cancer
and fibrotic disease and the emerging area of cancer-associated
fibrosis, aiming initially to progress them to clinical proof of
concept before evaluating options for further development and
potential value creation. The Company's lead fibrosis product
candidate, the selective ROCK2 inhibitor RXC007, is in development
for interstitial lung disease being evaluated in a Phase 2a trial
for idiopathic pulmonary fibrosis (IPF) with topline data expected
in Q1 2024. Redx's lead oncology product candidate, the Porcupine
inhibitor RXC004, being developed as a targeted treatment for
Wnt-ligand dependent cancers, is expected to report Phase 2 data in
combination with anti-PD-1 by end 2023. Redx's third drug
candidate, RXC008, a GI-targeted ROCK inhibitor for the treatment
of fibrostenotic Crohn's disease, is progressing towards a CTA
application in H2 2023.
The Company has a strong track record of discovering new drug
candidates through its core strengths in medicinal chemistry and
translational science, enabling the Company to discover and develop
differentiated therapeutics against biologically or clinically
validated targets. The Company's accomplishments are evidenced not
only by its two wholly-owned clinical-stage product candidates and
rapidly expanding pipeline, but also by its strategic transactions,
including the sale of pirtobrutinib (RXC005, LOXO-305), a
non-covalent (reversible) BTK inhibitor now approved by the US FDA
for adult patients with mantle cell lymphoma previously treated
with a covalent BTK inhibitor, and AZD5055/RXC006, a Porcupine
inhibitor targeting fibrotic diseases including IPF, which
AstraZeneca is progressing in a Phase 1 clinical study. In
addition, Redx has forged collaborations with Jazz Pharmaceuticals,
which includes JZP815, a pan-RAF inhibitor developed by Redx which
Jazz is now progressing through Phase 1 clinical studies, and an
early stage oncology research collaboration.
To subscribe to Email Alerts from Redx, please visit:
www.redxpharma.com/investor-centre/email-alerts/
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRANKBBNOBKDKPK
(END) Dow Jones Newswires
May 03, 2023 02:00 ET (06:00 GMT)
Redx Pharma (LSE:REDX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Redx Pharma (LSE:REDX)
Historical Stock Chart
From Apr 2023 to Apr 2024
